A citation-based method for searching scientific literature

Feiyue Zheng, Yi Zhang, Shuang Chen, Xiang Weng, Yuefeng Rao, Hongmei Fang. Biomed Pharmacother 2020
Times Cited: 27







List of co-cited articles
177 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Cytochrome P-450 3A4: regulation and role in drug metabolism.
F P Guengerich. Annu Rev Pharmacol Toxicol 1999
922
3


Obstacles to Brain Tumor Therapy: Key ABC Transporters.
Juwina Wijaya, Yu Fukuda, John D Schuetz. Int J Mol Sci 2017
42
3





Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism.
Antonius E van Herwaarden, Els Wagenaar, Cornelia M M van der Kruijssen, Robert A B van Waterschoot, Johan W Smit, Ji-Ying Song, Martin A van der Valk, Olaf van Tellingen, José W A van der Hoorn, Hilde Rosing,[...]. J Clin Invest 2007
172
3

Human mass balance study and metabolite profiling of 14C-niraparib, a novel poly(ADP-Ribose) polymerase (PARP)-1 and PARP-2 inhibitor, in patients with advanced cancer.
Lotte van Andel, Z Zhang, S Lu, V Kansra, S Agarwal, L Hughes, M M Tibben, A Gebretensae, L Lucas, M J X Hillebrand,[...]. Invest New Drugs 2017
15
6

Current trends in drug metabolism and pharmacokinetics.
Yuhua Li, Qiang Meng, Mengbi Yang, Dongyang Liu, Xiangyu Hou, Lan Tang, Xin Wang, Yuanfeng Lyu, Xiaoyan Chen, Kexin Liu,[...]. Acta Pharm Sin B 2019
43
3

Changes in DNA Damage Response Markers with Treatment in Advanced Ovarian Cancer.
Paul Kubelac, Catherine Genestie, Aurelie Auguste, Soizick Mesnage, Audrey Le Formal, Patricia Pautier, Sebastien Gouy, Philippe Morice, Enrica Bentivegna, Amandine Maulard,[...]. Cancers (Basel) 2020
11
9


Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial.
Richard T Penson, Ricardo Villalobos Valencia, David Cibula, Nicoletta Colombo, Charles A Leath, Mariusz Bidziński, Jae-Weon Kim, Joo Hyun Nam, Radoslaw Madry, Carlos Hernández,[...]. J Clin Oncol 2020
77
3

Endogenous DNA double-strand breaks: production, fidelity of repair, and induction of cancer.
Michael M Vilenchik, Alfred G Knudson. Proc Natl Acad Sci U S A 2003
429
3

Association of RAD51 with homologous recombination deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): analysis of the GeparSixto randomized clinical trial.
A Llop-Guevara, S Loibl, G Villacampa, V Vladimirova, A Schneeweiss, T Karn, D-M Zahm, A Herencia-Ropero, P Jank, M van Mackelenbergh,[...]. Ann Oncol 2021
7
14

A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline BRCA1/2 Mutations (ABRAZO).
Nicholas C Turner, Melinda L Telli, Hope S Rugo, Audrey Mailliez, Johannes Ettl, Eva-Maria Grischke, Lida A Mina, Judith Balmaña, Peter A Fasching, Sara A Hurvitz,[...]. Clin Cancer Res 2019
59
3

Germline BRCA1/2 mutation testing is indicated in every patient with epithelial ovarian cancer: A systematic review.
Marieke Arts-de Jong, Geertruida H de Bock, Christi J van Asperen, Marian J E Mourits, Joanne A de Hullu, C Marleen Kets. Eur J Cancer 2016
43
3

Frequent Homologous Recombination Deficiency in High-grade Endometrial Carcinomas.
Marthe M de Jonge, Aurélie Auguste, Lise M van Wijk, Philip C Schouten, Matty Meijers, Natalja T Ter Haar, Vincent T H B M Smit, Remi A Nout, Mark A Glaire, David N Church,[...]. Clin Cancer Res 2019
57
3

Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.
Jonathan Ledermann, Philipp Harter, Charlie Gourley, Michael Friedlander, Ignace Vergote, Gordon Rustin, Clare L Scott, Werner Meier, Ronnie Shapira-Frommer, Tamar Safra,[...]. Lancet Oncol 2014
910
3

Clinical whole-genome sequencing from routine formalin-fixed, paraffin-embedded specimens: pilot study for the 100,000 Genomes Project.
Pauline Robbe, Niko Popitsch, Samantha J L Knight, Pavlos Antoniou, Jennifer Becq, Miao He, Alexander Kanapin, Anastasia Samsonova, Dimitrios V Vavoulis, Mark T Ross,[...]. Genet Med 2018
71
3

An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients.
M A Vollebergh, E H Lips, P M Nederlof, L F A Wessels, M K Schmidt, E H van Beers, S Cornelissen, M Holtkamp, F E Froklage, E G E de Vries,[...]. Ann Oncol 2011
124
3

Modification of Homologous Recombination Deficiency Score Threshold and Association with Long-Term Survival in Epithelial Ovarian Cancer.
Jeffrey A How, Amir A Jazaeri, Bryan Fellman, Molly S Daniels, Suzanna Penn, Cara Solimeno, Ying Yuan, Kathleen Schmeler, Jerry S Lanchbury, Kirsten Timms,[...]. Cancers (Basel) 2021
7
14

ATR and p-ATR are emerging prognostic biomarkers and DNA damage response targets in ovarian cancer.
Wenlong Feng, Dylan C Dean, Francis J Hornicek, Jinglu Wang, Yanyan Jia, Zhenfeng Duan, Huirong Shi. Ther Adv Med Oncol 2020
4
25

Homologous recombination deficiency status-based classification of high-grade serous ovarian carcinoma.
Hisamitsu Takaya, Hidekatsu Nakai, Shiro Takamatsu, Masaki Mandai, Noriomi Matsumura. Sci Rep 2020
52
3

Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration.
Wassim Abida, Akash Patnaik, David Campbell, Jeremy Shapiro, Alan H Bryce, Ray McDermott, Brieuc Sautois, Nicholas J Vogelzang, Richard M Bambury, Eric Voog,[...]. J Clin Oncol 2020
157
3

The functional impact of variants of uncertain significance in BRCA2.
Romy L S Mesman, Fabienne M G R Calléja, Giel Hendriks, Bruno Morolli, Branislav Misovic, Peter Devilee, Christi J van Asperen, Harry Vrieling, Maaike P G Vreeswijk. Genet Med 2019
32
3

Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment.
Lenka Oplustilova, Kamila Wolanin, Martin Mistrik, Gabriela Korinkova, Dana Simkova, Jan Bouchal, Rene Lenobel, Jirina Bartkova, Alan Lau, Mark J O'Connor,[...]. Cell Cycle 2012
112
3

Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition.
Nuala McCabe, Nicholas C Turner, Christopher J Lord, Katarzyna Kluzek, Aneta Bialkowska, Sally Swift, Sabrina Giavara, Mark J O'Connor, Andrew N Tutt, Małgorzata Z Zdzienicka,[...]. Cancer Res 2006
865
3

The genomic landscape of metastatic breast cancer highlights changes in mutation and signature frequencies.
Lindsay Angus, Marcel Smid, Saskia M Wilting, Job van Riet, Arne Van Hoeck, Luan Nguyen, Serena Nik-Zainal, Tessa G Steenbruggen, Vivianne C G Tjan-Heijnen, Mariette Labots,[...]. Nat Genet 2019
109
3

Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline.
Alexi A Wright, Kari Bohlke, Deborah K Armstrong, Michael A Bookman, William A Cliby, Robert L Coleman, Don S Dizon, Joseph J Kash, Larissa A Meyer, Kathleen N Moore,[...]. Gynecol Oncol 2016
137
3

Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2).
Elizabeth M Swisher, Tanya T Kwan, Amit M Oza, Anna V Tinker, Isabelle Ray-Coquard, Ana Oaknin, Robert L Coleman, Carol Aghajanian, Gottfried E Konecny, David M O'Malley,[...]. Nat Commun 2021
23
4

The forefront of ovarian cancer therapy: update on PARP inhibitors.
M R Mirza, R L Coleman, A González-Martín, K N Moore, N Colombo, I Ray-Coquard, S Pignata. Ann Oncol 2020
76
3

An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity.
Oded Kopper, Chris J de Witte, Kadi Lõhmussaar, Jose Espejo Valle-Inclan, Nizar Hami, Lennart Kester, Anjali Vanita Balgobind, Jeroen Korving, Natalie Proost, Harry Begthel,[...]. Nat Med 2019
238
3

Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2.
Amit M Oza, Anna V Tinker, Ana Oaknin, Ronnie Shapira-Frommer, Iain A McNeish, Elizabeth M Swisher, Isabelle Ray-Coquard, Katherine Bell-McGuinn, Robert L Coleman, David M O'Malley,[...]. Gynecol Oncol 2017
150
3

Clinicopathological features of homologous recombination-deficient epithelial ovarian cancers: sensitivity to PARP inhibitors, platinum, and survival.
Asima Mukhopadhyay, Elizabeth R Plummer, Ahmed Elattar, San Soohoo, Bisha Uzir, Jennifer E Quinn, W Glenn McCluggage, Perry Maxwell, Harriet Aneke, Nicola J Curtin,[...]. Cancer Res 2012
73
3


The RECAP Test Rapidly and Reliably Identifies Homologous Recombination-Deficient Ovarian Carcinomas.
Lise M van Wijk, Sylvia Vermeulen, Matty Meijers, Manuela F van Diest, Natalja T Ter Haar, Marthe M de Jonge, Nienke Solleveld-Westerink, Tom van Wezel, Dik C van Gent, Judith R Kroep,[...]. Cancers (Basel) 2020
15
6

Bi-allelic alterations in DNA repair genes underpin homologous recombination DNA repair defects in breast cancer.
Robert W Mutter, Nadeem Riaz, Charlotte Ky Ng, Rob Delsite, Salvatore Piscuoglio, Marcia Edelweiss, Luciano G Martelotto, Rita A Sakr, Tari A King, Dilip D Giri,[...]. J Pathol 2017
34
3

Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors.
Janneke E Jaspers, Ariena Kersbergen, Ute Boon, Wendy Sol, Liesbeth van Deemter, Serge A Zander, Rinske Drost, Ellen Wientjens, Jiuping Ji, Amal Aly,[...]. Cancer Discov 2013
323
3

Prediction of BRCA1-association in hereditary non-BRCA1/2 breast carcinomas with array-CGH.
Simon A Joosse, Erik H van Beers, Ivon H G Tielen, Hugo Horlings, Johannes L Peterse, Nicoline Hoogerbrugge, Marjolijn J Ligtenberg, Lodewyk F A Wessels, Priscilla Axwijk, Senno Verhoef,[...]. Breast Cancer Res Treat 2009
108
3

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.
Joaquin Mateo, Suzanne Carreira, Shahneen Sandhu, Susana Miranda, Helen Mossop, Raquel Perez-Lopez, Daniel Nava Rodrigues, Dan Robinson, Aurelius Omlin, Nina Tunariu,[...]. N Engl J Med 2015
3

BRCAness digitalMLPA profiling predicts benefit of intensified platinum-based chemotherapy in triple-negative and luminal-type breast cancer.
Esther H Lips, Anne Benard-Slagter, Mark Opdam, Caroline E Scheerman, Jelle Wesseling, Frans B L Hogervorst, Sabine C Linn, Suvi Savola, Petra M Nederlof. Breast Cancer Res 2020
5
20

Detecting the mutational signature of homologous recombination deficiency in clinical samples.
Doga C Gulhan, Jake June-Koo Lee, Giorgio E M Melloni, Isidro Cortés-Ciriano, Peter J Park. Nat Genet 2019
87
3

Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models.
Hyoung Kim, Haineng Xu, Erin George, Dorothy Hallberg, Sushil Kumar, Veena Jagannathan, Sergey Medvedev, Yasuto Kinose, Kyle Devins, Priyanka Verma,[...]. Nat Commun 2020
59
3

Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer.
Neha Chopra, Holly Tovey, Alex Pearson, Ros Cutts, Christy Toms, Paula Proszek, Michael Hubank, Mitch Dowsett, Andrew Dodson, Frances Daley,[...]. Nat Commun 2020
64
3

Functional ex vivo assay to select homologous recombination-deficient breast tumors for PARP inhibitor treatment.
Kishan A T Naipal, Nicole S Verkaik, Najim Ameziane, Carolien H M van Deurzen, Petra Ter Brugge, Matty Meijers, Anieta M Sieuwerts, John W Martens, Mark J O'Connor, Harry Vrieling,[...]. Clin Cancer Res 2014
107
3

Homologous Recombination Deficiency Testing for BRCA-Like Tumors: The Road to Clinical Validation.
Marjolijn M Ladan, Dik C van Gent, Agnes Jager. Cancers (Basel) 2021
10
10

Prediction of breast cancer sensitivity to neoadjuvant chemotherapy based on status of DNA damage repair proteins.
Hideki Asakawa, Hirotaka Koizumi, Ayaka Koike, Makiko Takahashi, Wenwen Wu, Hirotaka Iwase, Mamoru Fukuda, Tomohiko Ohta. Breast Cancer Res 2010
69
3

Utility of DNA repair protein foci for the detection of putative BRCA1 pathway defects in breast cancer biopsies.
Henning Willers, Alphonse G Taghian, Chen-Mei Luo, Alejandro Treszezamsky, Dennis C Sgroi, Simon N Powell. Mol Cancer Res 2009
86
3

Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition.
Jane Goodall, Joaquin Mateo, Wei Yuan, Helen Mossop, Nuria Porta, Susana Miranda, Raquel Perez-Lopez, David Dolling, Dan R Robinson, Shahneen Sandhu,[...]. Cancer Discov 2017
226
3


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.